Back to top
more

ShockWave Medical (SWAV)

(Delayed Data from NSDQ)

$330.55 USD

330.55
429,386

+0.01 (0.00%)

Updated May 10, 2024 04:00 PM ET

After-Market: $330.53 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

Smart Beta ETF report for XHE

Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Shockwave Medical (SWAV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Shockwave Medical (SWAV) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Shockwave Medical (SWAV) Q1 Earnings and Revenues Top Estimates

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 38.46% and 5.66%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why the Market Dipped But Shockwave Medical (SWAV) Gained Today

In the latest trading session, Shockwave Medical (SWAV) closed at $328.99, marking a +0.04% move from the previous day.

Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now?

Smart Beta ETF report for GRPM

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

Sector ETF report for XHE

Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?

Style Box ETF report for GRPM

Shockwave Medical (SWAV) Advances While Market Declines: Some Information for Investors

Shockwave Medical (SWAV) concluded the recent trading session at $329, signifying a +0.45% move from its prior day's close.

Hologic (HOLX) Q2 Earnings Might Rise on GYN Surgical Growth

Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.

Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?

The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.

Is a Beat Likely for Edwards Lifesciences (EW) in Q1 Earnings?

The strong adoption of transcatheter heart valves is expected to have led to Edwards Lifesciences' (EW) growth in the first quarter.

Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?

Strength in Molecular Diagnostics business and GYN Surgical is likely to have driven Hologic's (HOLX) fiscal second-quarter performance.

Align Technology (ALGN) to Post Q1 Earnings: What's in Store?

Align Technology's (ALGN) first-quarter 2024 performance is likely to reflect the strength of the Clear Aligner and Systems & Services businesses.

J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft

J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.

What's in Store for Thermo Fisher (TMO) in Q1 Earnings?

Strength in Analytical Instrument and Laboratory Products and Services segments are likely to have driven Thermo Fisher's (TMO) first-quarter 2024 performance.

Why Shockwave Medical (SWAV) Could Beat Earnings Estimates Again

Shockwave Medical (SWAV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?

Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News

J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.